ons
mmendations on antiviral use may be found at http://www.cdc.gov/flu.)
kg
/day
into
es
doses
a
ded
Chemoprophylaxis
Duration: See Chemoprophylaxis & Outbreak Management Sections
75 mg capsule once a day
≤ 15 kg
30 mg once daily
15-23 kg
45 mg once daily
> 23-40 kg
60 mg once daily
> 40 kg
75 mg once daily
2 inhalations (10 mg) once a day
≥ 5 years
2 inhalations (10 mg) once a day
200 mg per day, either as a single daily dose or divided into 2 doses
1-9 years
5-8 mg/kg/day divided into 2 doses or as a
single daily dose (maximum 150 mg/kg/day)
9-12 years
200 mg/day divided into 2 doses
200 mg per day, either as a single daily dose or divided into 2 doses
1-9 years
9-12 years
5-8 mg/kg/day divided into 2 doses or as a
200 mg/day divided into 2 doses
single daily dose
(maximum 150 mg/kg/day)
spected. The adamantanes should not be used for infection or exposure to influenza A (H3N2) or influenza B.
pediatric population.
ÎÎAll residents with laboratory-confirmed influenza virus infection should
be treated with an appropriate influenza antiviral medication. After one
case of laboratory-confirmed influenza is detected in a facility resident,
all persons in the facility subsequently developing influenza-like illness
or other signs or symptoms consistent with influenza (eg, isolated altered
mental status in an elderly resident) should be considered for treatment
with an influenza antiviral medication (A-III).
ÎFor all institutional employees who are unable to receive influenza vaccine
Î
or in whom vaccine is contraindicated, or when the vaccine is expected to be
ineffective, antiviral medications should be used for chemoprophylaxis (B-III).
ÎÎAntiviral chemoprophylaxis should be continued for 14 days or for 7 days
after the onset of symptoms in the last person infected, whichever is
longer (A-II).
